Fig. 3From: Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomasOverall Survival and Progression Free Survival. Median progression free survival (PFS) was 1.4 months (range 0.2–9.4) and median overall survival (OS) was 4 months (range 0.5–13.8). Six month PFS was 12% and 6 month OS was 28%. Two patients had stable disease greater than 200 daysBack to article page